Drug interactions and pharmacokinetics: latest news

Drug interactions and pharmacokinetics resources

Drug interactions and pharmacokinetics features

Drug interactions and pharmacokinetics news from aidsmap

More news

Drug interactions and pharmacokinetics news selected from other sources

  • Women need more of the HIV drug Truvada than men to prevent infection

    Women need daily doses of the antiviral medication Truvada to prevent HIV infection while men only need two doses per week due to the way the drug accumulates in different body tissues, according to a new study from pharmacy researchers the University of North Carolina at Chapel Hill.

    04 March 2016 | Eurekalert Medicine & Health
  • Study: HIV can hide and grow in 'sanctuaries' in body after it's undetectable in blood

    The latest study appears to show a different type of "sanctuary," as the researchers called it, harboring cells with low levels of HIV replication that move into the blood. This suggests that virus growth could occur in a place where drug concentrations are very low.

    28 January 2016 | Washington Post
  • Many patients on new HCV medications at risk of drug-drug interactions

    Many patients taking direct acting antivirals (DAA) to treat hepatitis C virus (HCV) are at risk of clinically significant drug-drug interactions (DDIs), new research shows.

    23 December 2015 | Medscape (requires free registration)
  • Top five concerns people with HIV have about ageing: Scotland

    Through the Positive Persons' Forum and other initiatives, many people with HIV in Scotland have made it clear that they are very concerned about growing older with HIV. We have set out some of these concerns in the infographic below (or view it as a plain online image). The top 5 concerns were confidentiality, the effects of HIV medication, drug interactions, Financial stability and ignorance and stigma.

    12 August 2015 | HIV Scotland-
  • 'Lab on a card' can spot poor quality drugs

    The tool is known as a PAD (Paper Analytical Device) and is essentially a mini lab on a piece of card, Mercy explains. "It's simple, you apply the tablet on a specific area on the device, dip the card in water and wait for a colour reaction, then compare the results to a standard to interpret the results." Each of the cards contains 12 separate strips which react with a drug to create a "coloured bar code" that gives information about its chemical content.

    08 June 2015 | BBC Health
  • Almost Three Quarters of HIV/HCV Group May Have DDA-ARV Interactions

    Among 125 HIV/HCV-coinfected people taking antiretrovirals in a Denver group, 70% could have moderate or severe interactions with one of four common direct-acting antiviral (DAA) regimens for HCV.

    02 June 2015 | NATAP
  • Isentress (raltegravir) label update

    On February 18, 2015, FDA approved changes to the Isentress (raltegravir) label to include updated information regarding the coadministration of raltegravir and aluminum and/or magnesium containing antacid.

    19 February 2015 | FDA
  • Viral Load Reductions Persist With Less Efavirenz for HIV

    The virologic responses with reduced-dose efavirenz at 48 weeks have proven durable out to 96 weeks, ENCORE1 study results show.

    07 November 2014 | Medscape (requires free registration)
  • Change to recommended regimen for post-exposure prophylaxis (PEP)

    The Expert Advisory Group on AIDS (EAGA) has recommended a change in the recommended regimen for post-exposure prophylaxis from tenofovir/emtricitabine with Kaletra to tenofovir/emtricitabine with raltegravir.

    11 September 2014 | Expert Advisory Group on AIDS (EAGA)
  • Dosage of HIV drug may be ineffective for half of African-Americans

    Many African-Americans may not be getting effective doses of the HIV drug maraviroc. The initial dosing studies included mostly European-Americans, who generally lack a protein that is key to removing maraviroc from the body, resulting in higher concentrations of the drug in the blood. The current study shows that people with maximum levels of the protein CYP3A5 -- including nearly half of African-Americans -- end up with lower levels of maraviroc in their bodies.

    28 August 2014 | Eurekalert Medicine & Health
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap